Blueprint Medicines Corp (BPMC) Stock Price, Quote & News

Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell...

Industry: Biotechnology

Sector: Healthcare

Phone: (617) 374-7580

Website: www.blueprintmedicines.com

Address:

45 Sidney Street, Cambridge, United States

Night_Owl_Biotech Jun. 18 at 5:28 PM

Attached is a graph of $NVCR share price since 7/1/2024. NVCR surged in 12/2024 after a successful Phase 3 read in pancreatic. NVCR's TTF devices were first approved in FY2011 (I think) & do not generate traditional pharma type gross margins. Nonetheless, NVCR did $600MM in FY2024 sales. With the recent label expansion into NSCLC & the pancreatic data read, analysts forecast NVCR revenues to grow to over $1B by FY2029. NVCR trades at 2.1X FY2028 analyst consensus revenue estimates per Seeking Alpha. Fintel reports a higher estimate. $BPMC published its 14D9 yesterday that included Year 4 M&A multiples paid in BPMC peer M&A transactions. NVCR may not be an appropriate peer for BPMC. FWIW $EXEL trades at 3.5X FY2028 consensus. EXEL's first therapy was also approved 11/29/2012. $SNDX trades at 1.6X FY28 consensus (2 FDA approved therapies). This is not investment advice. $LEGN

1 · Reply

StockSamL Jun. 18 at 7:50 AM

$BPMC $VSTM $IBRX $GERN $FENC

1 · Reply

Night_Owl_Biotech Jun. 17 at 6:56 PM

$BPMC filed their 14D9 with the SEC today that includes, among other things, a copy of the financial forecast that included revenue projections provided $SNY Attached is a worksheet that compares the forecasts provided by BPMC to analyst consensus revenue estimates per Seeking Alpha & Fintel. It is interesting to note that analyst consensus revenue estimates are dramatically lower that what BPMC provided. It has been our experience that differences between the 2 are historically minor. If anything, it is our experience analysts are higher than management (esp. MRTX). We had noted that SNY was buying BPMC for $9.1B which was 0.51X 10-year projected revenues. Using BPMC prepared forecasts, SNY is buying BPMC for 0.37X 10 year revenue estimates. There is no other point or objective of this post. This is not investment advice. $XBI

1 · Reply

JarvisFlow Jun. 17 at 1:43 PM

Wells Fargo updates rating for Blueprint Medicines ( $BPMC ) to Equal-Weight, target set at 143 → 129.

0 · Reply

Quantumup Jun. 16 at 1:24 PM

Piper Sandler reit $COGT OW-$24/said "Remain OW-rated on $COGT shares heading July's pivotal readout for bezuclastinib from the SUMMIT Part 2 trial." $BPMC Piper +'d, "While we have long viewed bezu's profile in non-AdvSM (non-advanced systemic mastocytosis) as differentiated and best-in-class, we have fielded a number of questions around what to expect for this next update and potential stock implications. Herein, we walk through our thoughts on the efficacy and safety bar for success, which largely aligns with management's recently-articulated bar (>50% higher pbo-adjusted benefit on TSS (total symptom score) vs. competitor avapritinib, with ~≤10% Gr. 3 ALT/AST elevations and no cases of liver injury) -- and we believe investors are largely in agreement on this. While shares have had a nice run in recent weeks (up some 48% in the last ~month), we think the risk/reward skews very favorably not only into SUMMIT data, but two additional pivotal readouts (in AdvSM and GIST) later this year."

0 · Reply

BioTechChap Jun. 13 at 9:34 AM

$CLDX $JSPR $BPMC https://ir.celldex.com/news-releases/news-release-details/celldex-presents-unprecedented-76-week-results-barzolvolimab

0 · Reply

Wrangler4 Jun. 11 at 10:45 AM

$AGIO $ARQT $BPMC $TARS old chart , bull siht chart Since the inclusion of DCPH …long gone , sold cheap due to narcissistic senior execs, poor CEO, Steve Hoerter a buffoon that came from AGIO , was only a Commercial Officer before CEO, had no business being a CEO and the former CEO was a smug arrogant narcissist, like Trump. Agio..had the same with the Napoleon syndrome suffered by Schenkien, then he picked a puppet from his Celgene days that was a failure at Bunge ( BG) and put her in charge in face only..then a laid off middle manager from Alexion, Goff was picked The line up of CEO’s here was a total train wreck . SELL

0 · Reply

Night_Owl_Biotech Jun. 11 at 1:40 AM

$TARS trades at 0.17X cumulative 10-year analyst consensus revenue estimates. Attached see a range of like multiples from 14 peer commercial-stage bio M&A transactions. You'll note peers were acquired at a median 10-year revenue multiple of 0.40X from the larger group (but ranges from 0.26 to 0.78X). TARS generates 93% gross margins on product sales which appears competitive with these peers. Now that TARS has traded down to a more reasonable market cap, we'd genuinely appreciate perspectives from TARS' investors as to whether TARS is worth a peer multiple. As we understand it, TARS has patents on Xdemvy protecting it through 12/14/2038. NOTE: $BPMC multiple uses analyst consensus since the 14A/14D9 filing has not been made. This is not investment advice. Next up will be $ARQT & $AGIO. Thank you. $XBI

0 · Reply

KingdomFasho Jun. 9 at 4:27 PM

$BPMC is it actually plausible for this stock to keep running past 128 or is it mostly institutional owned/ not going anywhere?

0 · Reply

YasirTrades Jun. 8 at 8:29 PM

GLMD setup looks like $ONC (+40%), $KYMR (+50%), $MLTX (+16% on takeover buzz), and $BPMC (+26% on $9B buyout). GLMD still under $1.40, $12+ book, low float, no dilution. Chart’s coiled. One spark and this can rip. GLMD #biotech #smallcaps #squeeze

0 · Reply

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC

SNY

Jun 12, 2025, 6:01 PM EDT - 13 days ago

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses

Jun 2, 2025, 2:51 PM EDT - 23 days ago

Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz

BMY BNTX MRK SNY

Jun 2, 2025, 12:48 PM EDT - 23 days ago

Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines

SNY

Jun 2, 2025, 11:46 AM EDT - 23 days ago

Sanofi-Blueprint deal is a bullish signal about biotech M&A

SNY

Jun 2, 2025, 6:50 AM EDT - 24 days ago

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.

Jun 2, 2025, 1:25 AM EDT - 24 days ago

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

SNY

Jun 2, 2025, 1:24 AM EDT - 24 days ago

Sanofi buys US biopharma group Blueprint in $9.1 bln deal

SNY

Jun 2, 2025, 1:22 AM EDT - 24 days ago

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

SNY

Jun 2, 2025, 1:00 AM EDT - 24 days ago

Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

SNY

May 20, 2025, 8:00 AM EDT - 5 weeks ago

VantAI Expands Strategic Collaboration with Blueprint Medicines to Advance Induced Proximity Drug Discovery

May 1, 2025, 2:01 PM EDT - 7 weeks ago

Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 2 months ago

Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

Apr 25, 2025, 8:00 AM EDT - 2 months ago

Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Apr 7, 2025, 5:37 AM EDT - 2 months ago

Blueprint Medicines Continues Targeting Mast Cells For Potential Billion-Dollar Growth

Mar 31, 2025, 8:00 AM EDT - 3 months ago

Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference

Feb 28, 2025, 8:00 AM EST - 4 months ago

Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress

Feb 13, 2025, 11:32 AM EST - 4 months ago

Blueprint Medicines Corporation (BPMC) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 7:00 AM EST - 4 months ago

Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results

Feb 5, 2025, 8:00 AM EST - 5 months ago

Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Jan 12, 2025, 4:00 PM EST - 5 months ago

Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth

Dec 18, 2024, 8:00 AM EST - 6 months ago

Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 7, 2024, 12:30 PM EST - 7 months ago

Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting

Nov 15, 2024, 5:26 PM EST - 7 months ago

Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs

Nov 14, 2024, 3:18 PM EST - 7 months ago

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst

Oct 30, 2024, 2:29 PM EDT - 8 months ago

Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 7:00 AM EDT - 8 months ago

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

Oct 16, 2024, 8:00 AM EDT - 9 months ago

Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Sep 11, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Has Launched An Inquiry Into Whether Blueprint Medicines Corporation Violated Securities Laws And Impacted Investors Are Invited To Join

Sep 10, 2024, 11:00 AM EDT - 10 months ago

Blueprint Medicines Corporation Is Being Investigated For Securities Fraud And Stakeholders With Losses Should Contact The Schall Law Firm

Sep 10, 2024, 8:00 AM EDT - 10 months ago

Blueprint Medicines to Present at Upcoming Investor Conferences

$The Schall Law Firm Invites Investors To Join An Inquiry Into Blueprint Medicines Corporation For Possibly Committing Securities Related Infractions$

Sep 9, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Invites Investors To Join An Inquiry Into Blueprint Medicines Corporation For Possibly Committing Securities Related Infractions

Sep 7, 2024, 11:00 AM EDT - 10 months ago

Blueprint Medicines Corporation May Have Engaged In Securities Fraud And Shareholder Participation In An Investigation Is Encouraged By The Schall Law Firm

Sep 5, 2024, 11:00 AM EDT - 10 months ago

Blueprint Medicines Corporation May Have Defrauded Shareholders And The Schall Law Firm Wants Those With Losses To Reach Out

Sep 3, 2024, 11:00 AM EDT - 10 months ago

Blueprint Medicines Corporation May Have Defrauded The Public And The Schall Law Firm Seeks Shareholder Participation In An Inquiry

Sep 2, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Is Looking Into Whether Blueprint Medicines Corporation Committed Securities Related Improprieties And Investors Should Reach Out

$Shareholders Can Now Join The Schall Law Firm In Investigating Securities Related Infractions By Blueprint Medicines Corporation$

Sep 1, 2024, 11:00 AM EDT - 10 months ago

Shareholders Can Now Join The Schall Law Firm In Investigating Securities Related Infractions By Blueprint Medicines Corporation

Aug 31, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Is Looking Into Blueprint Medicines Corporation's Possible Securities Fraud And Investors Are Invited To Assist

Aug 30, 2024, 11:00 AM EDT - 10 months ago

Blueprint Medicines Corporation May Have Violated Securities Regulations And The Schall Law Firm Seeks Shareholders' Help In The Inquiry

Aug 29, 2024, 11:00 AM EDT - 10 months ago

Investors Are Encouraged To Contact The Schall Law Firm About An Investigation Into Blueprint Medicines Corporation's Securities Related Impropriety

Aug 28, 2024, 11:00 AM EDT - 10 months ago

Blueprint Medicines Corporation May Have Committed Securities Fraud And The Schall Law Firm Seeks Shareholders To Join An Inquiry

Aug 26, 2024, 11:00 AM EDT - 10 months ago

Blueprint Medicines Corporation Is Being Looked Into For Possible Securities Fraud And The Schall Law Firm Invites Shareholders To Help

Aug 24, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Is Investigating Blueprint Medicines Corporation For Securities Fraud And Stockholders With Losses Are Invited To Contribute

Night_Owl_Biotech Jun. 18 at 5:28 PM

1 · Reply

StockSamL Jun. 18 at 7:50 AM

$BPMC $VSTM $IBRX $GERN $FENC

1 · Reply

Night_Owl_Biotech Jun. 17 at 6:56 PM

1 · Reply

JarvisFlow Jun. 17 at 1:43 PM

Wells Fargo updates rating for Blueprint Medicines ( $BPMC ) to Equal-Weight, target set at 143 → 129.

0 · Reply

Quantumup Jun. 16 at 1:24 PM

0 · Reply

BioTechChap Jun. 13 at 9:34 AM

$CLDX $JSPR $BPMC https://ir.celldex.com/news-releases/news-release-details/celldex-presents-unprecedented-76-week-results-barzolvolimab

0 · Reply

Wrangler4 Jun. 11 at 10:45 AM

0 · Reply

Night_Owl_Biotech Jun. 11 at 1:40 AM

0 · Reply

KingdomFasho Jun. 9 at 4:27 PM

$BPMC is it actually plausible for this stock to keep running past 128 or is it mostly institutional owned/ not going anywhere?

0 · Reply

YasirTrades Jun. 8 at 8:29 PM

0 · Reply

YasirTrades Jun. 8 at 8:25 PM

GLMD setup reminds me of $KYMR (+41% on trial data), $MLTX (+20% on takeover buzz), $BPMC (+26% on $9B buyout), and $CRBU (+13% on volume/trial updates). $ is under $1.40 with $12+ book, low float, no dilution. Just needs a catalyst. GLMD #biotech #smallcaps

0 · Reply

QuiverQuant Jun. 6 at 2:58 PM

New Analyst Forecast: $BPMC Given 'Market Perform' Rating Read more on $BPMC: https://www.quiverquant.com/news/New+Analyst+Forecast%3A+%24BPMC+Given+%27Market+Perform%27+Rating

0 · Reply

JarvisFlow Jun. 5 at 5:40 PM

Morgan Stanley has updated their rating for Blueprint Medicines ( $BPMC ) to Equal-Weight with a price target of 129.

0 · Reply

JarvisFlow Jun. 5 at 1:00 PM

UBS has adjusted their stance on Blueprint Medicines ( $BPMC ), setting the rating to Neutral with a target price of 88 → 129.

0 · Reply

anachartanalyst Jun. 4 at 1:01 PM

$BPMC https://anachart.com/wp-content/uploads/ana_temp/1749042095_soc-img.jpg

0 · Reply

JarvisFlow Jun. 4 at 1:00 PM

Citigroup updates rating for Blueprint Medicines ( $BPMC ) to Neutral, target set at 83 → 129.

0 · Reply

JarvisFlow Jun. 3 at 2:14 PM

JMP Securities has adjusted their stance on Blueprint Medicines ( $BPMC ), setting the rating to Market Perform.

0 · Reply

pissed_of_retards Jun. 3 at 1:26 PM

$NVAX $BPMC had accounting value $350M + value of pipeline and was sold for $8B. Novavax has accounting value roughly $100M and if they sell combo for $2B they will have accounting value $2B plus the value of future pipeline.

0 · Reply

JarvisFlow Jun. 3 at 11:30 AM

Stephens & Co. has adjusted their stance on Blueprint Medicines ( $BPMC ), setting the rating to Equal-Weight with a target price of 150 → 135.

0 · Reply

TheDayTradingAcademy Jun. 3 at 9:48 AM

Shares of $BPMC surged +26.09% at $127.79, after the U.S. biopharmaceutical company agreed to be acquired by $SNY for $129 per share, in a deal worth approximately $9.5 billion. Shares of French based Sanofi were just fractionally lower. Blueprint stock was up +28.87% in the past month, +46.51% in 2025 & +25.42% y/y, with a market cap of $8.25B.

0 · Reply

CH_Expat Jun. 3 at 6:25 AM

$MLTX $BPMC You can always follow me for good ideas. All you need to do is not sell too early like I do.

0 · Reply

BuyNowUnlimited Jun. 3 at 4:25 AM

$BPMC $ANY spent their money to buy out $BPMC instead of $TGTX … sigh

0 · Reply

Market Cap	8.28B
Revenue (ttm)	508.82M
Net Income (ttm)	-67.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-13.19%
Debt to Equity Ratio	1.13

Volume	2,444,600
Avg Vol	3,220,276
Day's Range	N/A - N/A
Shares Out	64.58M
Stochastic %K	66%
Beta	0.84
Analysts	Sell
Price Target	$132.42